347 related articles for article (PubMed ID: 25115050)
1. Differences in quality of life between pediatric sickle cell patients who used hydroxyurea and those who did not.
Nwenyi E; Leafman J; Mathieson K; Ezeobah N
Int J Health Care Qual Assur; 2014; 27(6):468-81. PubMed ID: 25115050
[TBL] [Abstract][Full Text] [Related]
2. Daily home opioid use in adults with sickle cell disease: The PiSCES project.
Smith WR; McClish DK; Dahman BA; Levenson JL; Aisiku IP; de A Citero V; Bovbjerg VE; Roberts JD; Penberthy LT; Roseff SD
J Opioid Manag; 2015; 11(3):243-53. PubMed ID: 25985809
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea for children with sickle cell disease.
Heeney MM; Ware RE
Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
[TBL] [Abstract][Full Text] [Related]
4. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
Health Qual Life Outcomes; 2017 Jul; 15(1):136. PubMed ID: 28679417
[TBL] [Abstract][Full Text] [Related]
5. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
[TBL] [Abstract][Full Text] [Related]
6. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE
Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
8. The role of hydroxyurea in the management of sickle cell disease.
Davies SC; Gilmore A
Blood Rev; 2003 Jun; 17(2):99-109. PubMed ID: 12642122
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea therapy in adult Nigerian sickle cell disease: a monocentric survey on pattern of use, clinical effects and patient's compliance.
Adewoyin AS; Oghuvwu OS; Awodu OA
Afr Health Sci; 2017 Mar; 17(1):255-261. PubMed ID: 29026400
[TBL] [Abstract][Full Text] [Related]
10. Use of hydroxyurea in children with sickle cell disease: what comes next?
Ohene-Frempong K; Smith-Whitley K
Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
Al-Jam'a AH; Al-Dabbous IA
Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
[TBL] [Abstract][Full Text] [Related]
12. Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers.
Madden NA; Jones GL; Kalpatthi R; Woods G
J Pediatr Hematol Oncol; 2014 Aug; 36(6):e382-6. PubMed ID: 24714503
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
Anderson N
Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
[TBL] [Abstract][Full Text] [Related]
14. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.
Salvia AC; Figueiredo MS; Braga JA; Pereira DF; Brighenti FL; Koga-Ito CY
J Oral Pathol Med; 2013 Aug; 42(7):570-5. PubMed ID: 23278631
[TBL] [Abstract][Full Text] [Related]
16. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
[TBL] [Abstract][Full Text] [Related]
17. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease.
Badawy SM; Thompson AA; Penedo FJ; Lai JS; Rychlik K; Liem RI
Eur J Haematol; 2017 Jun; 98(6):608-614. PubMed ID: 28306171
[TBL] [Abstract][Full Text] [Related]
18. Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea.
Thornburg CD; Calatroni A; Panepinto JA
J Pediatr Hematol Oncol; 2011 May; 33(4):251-4. PubMed ID: 21516020
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea treatment in children with sickle cell anemia in Central America and the Caribbean countries.
Svarch E; Machín S; Nieves RM; Mancia de Reyes AG; Navarrete M; Rodríguez H
Pediatr Blood Cancer; 2006 Jul; 47(1):111-2. PubMed ID: 16550531
[No Abstract] [Full Text] [Related]
20. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]